| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding | |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | Entrez:930 MIM:107265 HGNC:HGNC:1633 Ensembl:ENSG00000177455 AllianceGenome:HGNC:1633 | |
| Description | CD19 molecule | |||||
| GTO ID | GTC1111 |
| Trial ID | JPRN-jRCT1080223858 |
| Disease | Diffuse Large B-Cell Lymphoma | B-Cell Lymphoma | Primary Mediastinal B-Cell Lymphoma | Follicular Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | KTE-C19 |
| Phase | Phase2 |
| Recruitment status | Not Recruiting |
| Title | A Phase 2 Multicenter, Open-label, Single-arm Study of KTE-C19 in Japanese Patients with Refractory or Relapsed Large B Cell Lymphoma |
| Year | 2018 |
| Country | Japan |
| Company sponsor | Gilead Sciences K.K. |
| Other ID(s) | JapicCTI-183914 |
| Cohort 1 | |||||||||
|
|||||||||